A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

May 31, 2031

Conditions

Angelman Syndrome

Interventions

GENETIC

MVX-220

AAVhu68 viral vector

Trial Locations (1)

RECRUITING

Rush University Medical Center, Chicago

All Listed Sponsors

lead

MavriX Bio, LLC

INDUSTRY

NCT07181837 - A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome | Biotech Hunter | Biotech Hunter